Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARX517 + abiraterone acetate + prednisone
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
ARX517 + abiraterone acetate + prednisone is an investigational multi-drug regimen being explored for the treatment of **metastatic castration-resistant prostate cancer (mCRPC)**. The regimen combines: - **ARX517**, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), delivering a microtubule inhibitor payload specifically to PSMA-expressing tumor cells, causing cytotoxicity and apoptosis. ARX517 uses a noncleavable linker for stability and selective delivery[2][8]. - **Abiraterone acetate**, a prodrug of abiraterone, inhibits CYP17A1, blocking androgen biosynthesis and reducing testosterone and cortisol, while also inducing mineralocorticoid excess[1][7]. - **Prednisone**, a glucocorticoid, compensates for abiraterone-induced cortisol reduction and helps manage mineralocorticoid-related adverse events[1]. The combination intends to leverage ARX517’s cytotoxic specificity alongside hormonal blockade from abiraterone acetate and supportive corticosteroid therapy with prednisone.
- Other names
- abiraterone acetate + prednisoneARX517 + abiraterone acetate + prednisone
02
Targets
GR (Glucocorticoid receptor)AR (Adrenergic receptors)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ARX517 + abiraterone acetate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARX517 + abiraterone acetate + prednisone.